Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) is making waves in the healthcare industry with the launch of its groundbreaking pulse lavage irrigation treatment. This innovative solution is set to revolutionize surgical procedures by replacing commonly used IV bags. Sonoma’s pulse lavage irrigation treatment utilizes their patented Microcyn technology, which is based on stabilized hypochlorous acid (HOCl). This technology has a wide range of applications, including wound care, eye care, oral and nasal care, dermatological conditions, podiatry, animal healthcare, and non-toxic disinfectants.
Having already introduced this product in Europe, Sonoma is now bringing it to the United States. They will be showcasing their pulse lavage irrigation treatment at the Symposium on Advanced Wound Care (SAWC) Fall Conference in Las Vegas, with demonstrations available from November 3 to November 5 at booth 118. The product is expected to be commercially available in the U.S. starting November 2023.
Sonoma’s development of this new application of their wound care technology was driven by the need for a non-toxic irrigation solution that can prevent infection and improve healing time. The pulse lavage irrigation treatment replaces commonly used non-antimicrobial saline and aggressive rinsing solutions with the safe and effective Microcyn Technology. This technology aids in the reduction of microorganisms, is non-toxic, and possesses regenerative properties, which are critical for preventing infection and promoting wound healing. What’s more, Sonoma’s pulse lavage container is cost competitive with IV bags, which are currently the standard of care.
This innovative application of pulse lavage irrigation treatment complements various surgical procedures, including abdominal, laparoscopic, and periprosthetic joint infection procedures. It is safe for use on soft tissues, mucous membranes, bones, tendons, muscles, cartilage, and even nerve tissue. The solution can be easily disposed of without requiring biohazard precautions and comes in a spikeable and unbreakable 5-liter container.
Amy Trombly, CEO of Sonoma Pharmaceuticals, expressed her excitement about the company’s latest offering, saying, Sonoma continues to lead in the innovation of products that improve healing times and prevent infection, while being safe for all parts of the body. Our irrigation solution is an opportunity to fulfill the unmet need of combined safety, effectiveness, and convenience in intraoperative pulse lavage irrigation treatments, and we are excited to bring this new technology to the United States medical community.
For more information about Sonoma’s pulse lavage irrigation treatment or to pre-order the solution, interested parties can contact [email protected].
